Clinical Trial

The Implementation of the Go Wish Game to Promote Advance Care Planning in Onco- Hematologic Disease

Study acronym: OHGW-ACP
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 7, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a mixed-method, device-free and drug-free multicenter interventional study. The study aims at facilitating end-of-life conversations within the doctor-patient relationship through the use of the Go Wish Game (GWG) and supporting patients, their caregivers and healthcare professionals to complete Advance Care Panning documentation. The GWG helps people clarify and identify their priorities, should they be affected by a chronic, disabling and potentially non-healing illness. In fact, the GWG consists of a small deck of cards, and on each card is a concrete action or situation that may be important to a person at the end of life. The "Onco-hema Go wish-ACP" project aims to evaluate the feasibility of a Go Wish Game-based intervention with patients with refractory lymphoma, leukemia or multiple myeloma or advanced solid tumors with prognosis \> 3 months. In terms of secondary objectives, the study aims to. * Evaluate and compare the intervention with hematology and oncology patients in terms of: - Other feasibility indicators; Involvement in CCP pathways; Quality of communication; Meaning of life; Impact on hope; through a series of questionnaires administered to patients and caregivers involved in the intervention * Qualitatively assess the acceptability of the intervention in terms of recruitment and delivery with patients and caregivers through semi-structured interviews and with professionals through Focus Groups (FGs). * To analyze the clinical records of enrolled patients in terms of: values and preferences; awareness of prognosis; end-of-life choices and shared decision-making on treatment decisions.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-01-21; most recent amendment 2026-05-04.
Status change: Not Yet Recruiting → Recruiting 2025-06-09
Trial Details
NCT Number NCT06795815
Lead Sponsor Azienda USL Reggio Emilia - IRCCS
Conditions Leukemia, Multiple Mieloma, Advanced Solid Tumors, Lymphoma, Oncology, Hematologic Diseases
Enrollment 75 participants
Start Date 2025-06-30
Primary Completion 2026-07 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2026-05-07